Posts

NAMs-Related Presentations at the Upcoming 65th SOT Annual Meeting in San Diego

on
The 65th SOT Annual Meeting and ToxExpo is scheduled for March 22-25, 2026, at the San Diego Convention Center. The event will feature over 70 scientific sessions and 2,000 poster presentations, including topics on emerging approaches such as NAMs. No specific NAMs-related presentations are detailed yet; prior SOT 2025 (March 16-20, Orlando) included multiple NAMs sessions like 'Utilizing New Approach Methodologies for Regulatory Assessment of Developmental Neurotoxicity' and posters on computational toxicology and neurotoxicity assays. Companies like Concept Life Sciences, NAMSA, and others are attending and highlighting NAM-related innovations in sessions and booths. Sources:

Ipsen Withdraws Tazverik from Market Due to Secondary Malignancy Safety Concerns

on

BMS Receives FDA Approval for Sotyktu in Psoriatic Arthritis Treatment

on

Roche's Oral SERD Giredestrant Fails Phase 3 persevERA Trial in First-Line Breast Cancer

on

Incyte Receives FDA CRL for Zynyz NSCLC Expansion Due to Issues at Novo Nordisk's Catalent Indiana Facility, Becoming Third Affected Company

on

FDA Approves Leucovorin for Rare Cerebral Folate Deficiency Without New Trial Data

on

Novo Nordisk Receives FDA Warning Letter for Failing to Report Ozempic Safety Signals Including Deaths

on

Capricor Shares Rise as FDA Sets August 2026 Decision Date for Deramiocel in Duchenne Muscular Dystrophy After Prior Rejection

on

Ascletis Reports Positive Phase 2 Data for Quarterly-Dosing GLP-1 ASC30 in Obesity

on

Alfasigma Licenses GSK's Linerixibat for PBC Itch in Up to $690M Deal

on

AbbVie and Gubra Report Positive Phase 1 Obesity Data for ABBV-295

on

Bristol Myers Squibb Announces Positive Phase 3 Results for Mezigdomide in Multiple Myeloma

on

AbbVie Reports Up to 9.8% Weight Loss in Phase 1 Trial of Gubra-Partnered Amylin Analogue ABBV-295

on